Parker Institute for Cancer Immunotherapy
@parkerici
Followers
11K
Following
4K
Media
962
Statuses
4K
Our mission is to accelerate the development of breakthrough immune therapies to turn all cancers into curable diseases.
San Francisco, CA
Joined February 2016
Catch Dr. Catherine Wu’s keynote on Therapeutic cancer vaccines at #ESMO25 on Oct 19! Proud to see PICI and Dana-Farber researchers sharing major findings in breast, lung and bladder cancers. Learn more about DFCI’s work here:
0
0
1
Congrats to PICI researcher Philip J. Kranzusch, Ph.D., @DanaFarber for being honored by @BlavatnikAwards for his work on immunity’s ancient origins. Learn more:
Just announced! The 2025 Blavatnik Awards National Laureates 🏅 Philip Kranzusch @DanaFarber @harvardmed Immunity’s ancient origins 🏅 Elaina Sutley @UnivOfKansas Building resilience to disasters 🏅 Frank Leibfarth @UNC Turning plastic waste into solutions https://t.co/aicrY7PCcy
0
0
4
At #AGENTICby12080, PICI CEO @DrKarenKnudsen discussed how immunotherapy and AI are transforming cancer care. @GRogow shares a recap of Dr. Knudsen’s keynote address in #AfterTreatment:
after-treatment.com
Dr. Karen Knudsen, former CEO of the American Cancer Society and current CEO of the Parker Institute for Cancer Immunotherapy, lays out the possibilities.
0
0
3
Congrats to Mary Brunkow, Shimon Sakaguchi & PICI scientific advisor & former CSO Fred Ramsdell, for receiving the @NobelPrize for their work on peripheral immune tolerance. This recognition reinforces why deep study of the immune system remains central to scientific progress.
BREAKING NEWS The 2025 #NobelPrize in Physiology or Medicine has been awarded to Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi “for their discoveries concerning peripheral immune tolerance.”
0
3
19
Great conversation between PICI CEO @DrKarenKnudsen and @irat1onal on the @ProgressPotent1 podcast. Listen here to learn about Dr. Knudsen’s career journey and what PICI is doing to turn all cancers into curable diseases:
progresspotentialpossibilities.com
Turning All Cancers Into Curable Diseases - Dr. Karen Knudsen MBA PhD - CEO, Parker Institute for Cancer Immunotherapy, joins me on Progress, Potential, And Possibilities #ProstateCancer #CARTCellTherapy #CheckpointInhibitors #TumorAntigens #TumorMicroenvironment
0
2
7
🎉 Congratulations to PICI portfolio company Georgiamune for being named by @FierceBiotech as one of the most innovative and promising biotechs for their work making immunotherapies effective in more cancer patients! Read more about Georgiamune: https://t.co/AXGw59ixNc.
fiercebiotech.com
From advancing radically new therapies to refining existing modalities, this year’s Fierce 15 companies are pushing the envelope and giving us a reason for optimism.This year has been chock-full of...
Introducing Fierce Biotech’s 2025 class of Fierce 15 winners. From advancing radically new therapies to refining existing modalities, this year’s companies are pushing the envelope and giving us a reason for optimism.
0
0
3
PICI is proud to announce the 2025 Early Career Researcher awardees: 🟣 Mehdi Benzaoui @WeillCornell 🟣 Alisa Dietl @GladstoneInst 🟣 Lindsey Draper @UCSF 🟣 Hyuncheol Jung @UCSF 🟣 Theodore Roth @StanfordMed Congrats to all! Learn more: https://t.co/BGEsjNPN37
1
5
26
The @AACR #CancerProgressReport 2025 shows how #CancerResearch is changing lives - and what more needs to be done. PICI is proud to catalyze progress in immunotherapy, to help bring lab discoveries to patients in need. Read more:
cancerprogressreport.aacr.org
The AACR Cancer Progress Report highlights how research improves lives and how ongoing federal funding is needed to eradicate cancer.
0
0
2
🎉Congrats to PICI-founded company @DispatchBio for being named an #Endpoints11 company! This award recognizes biotech’s most promising startups, and in the case of Dispatch, their innovative approach to developing a universal treatment for difficult-to-treat solid tumors.
We’re honored to be named a 2025 #Endpoints11 company by @endpts. This award underscores the importance of our mission to help create a world where all cancer patients can be cured.Thank you to all who are working to bring this vision to life.
0
0
2
Fantastic collaboration between @GuardantHealth and @parkerici Methyl-based ctDNA tumor fraction changes predict long-term clinical benefit from immune checkpoint inhibitors in RADIOHEAD, a real-world pan-cancer study
aacrjournals.org
AbstractCurrent response evaluation methods have accuracy limitations. Monitoring with a ctDNA methylation-based tumor fraction (TF) may provide a more accurate assessment of tumor burden across...
0
2
13
A new protocol from PICI Investigator Lili Yang, PhD, (@UCLA) published in @CellPressNews, lets scientists track cancer-fighting cells in real time as they move through the body — offering insight for safer, more effective therapies that combine precision targeting with immune
0
2
11
At #SITC25 Ira Mellman of the @parkerici and Medici Therapeutics will be honored for the 2025 Richard V. Smalley Memorial Award and Lectureship! He will give a presentation on Nov. 8 – join virtually or attend in person. https://t.co/7tUO28mKyk
0
2
6
Join us in celebrating PICI Board Member and President of @calimmunology, Eric Esrailian, MD, MPH, for being invited to join @TheAcademy of Motion Picture Arts and Sciences! Among other contributions to cinema, Dr. Esralian served, alongside PICI Founder and Chairman @sparker,
Thank you @TheAcademy for this honor alongside so many people I love & admire & I am looking forward to the next chapter! Thank you to so many friends, mentors & partners who teach me, inspire me, support me & push me in every industry, investment, business & project. Everything
0
0
1
Collection highlight from @Cancer_Cell: Mutant KRAS peptide targeted CAR-T cells engineered for cancer therapy https://t.co/b8gtAGEtKk
@PennMedicine
1
37
144
Can immune signals in blood predict ICI response in early-stage hormone receptor-positive breast cancer? A new PICI-supported study with contributions from @EMittendorfMD and @VanAllenLab (@DanaFarber) maps CD8+ T cell turnover, interferon activity in B cells and monocyte
0
1
12
With solid tumors representing ~90% of cancers, Dispatch Bio is engineering a universal treatment across solid tumors, leveraging its first-in-class Flare platform to help create a world where all #cancer patients can be cured. Learn more: https://t.co/Ps48IbX2Cg
1
6
13
Startup Dispatch Bio has ambitious plan, research superstars and $216 million to battle cancer https://t.co/o5YQPkk8Zl
bizjournals.com
Dispatch Bio debuts with $216M funding, including a fresh $100 million round, and aims to transform solid tumor treatment via a novel approach combining viral vectors and immunotherapies.
0
3
5
Dispatch Bio raises $216 million for solid tumor immunotherapy Solid tumors have challenged CAR-T developers Sean Parker, ARCH launch biotech developing a universal immunotherapy
statnews.com
Dispatch Bio is developing a universal immunotherapy by trying to install a synthetic protein — called the “flare” antigen — on every cancer cell in a patient's body.
1
4
18
Parker Institute, ARCH unveil CAR-T biotech with $216M to crack solid tumors
endpoints.news
Dispatch Bio unveils $216M plan to tackle solid tumors with viral vector-CAR-T combo, led by Carl June & Chris Garcia, backed by PICI, ARCH & Bristol Myers Squibb. Clinical trials planned for 2024.
1
11
45